 Gilead Sciences Inc. on Friday said it scored a key victory in securing the rights to its hepatitis C treatment, after an arbitration panel ruled in its favor over Roche Holding AG's claim on the lucrative drug.. The panel ruled on Thursday that Roche failed to establish any of its claims to sofosbuvir, the key ingredient in Sovaldi, according to a filing from Gilead.. A...
  